An Innovative Approach in Treating Heart Failure
Global medical technology and innovation company, LivaNova PLC, conducts the large medical device study ANTHEM-HFrEF to evaluate whether autonomic regulation therapy will benefit patients with symptomatic heart failure and reduced ejection fraction. The trial is performed by the US-based CRO CCSF, with SCIRENT responsible for managing the European sites. The prospective, international, randomized, controlled clinical […]
SCIRENT Supports Phase IIa Study of BC 007 for the Treatment of Heart Failure
Drug developer Berlin Cures has launched a phase IIa trial for its β1-adrenoceptor autoantibody (β1-AAb) neutralizing ssDNA product BC 007.
COVID-19: Keeping up Trial Safety and Progress
The global COVID-19 pandemic has largely impacted the healthcare system and also the conduct of clinical trials. Many sponsors have had to adapt clinical trial operations to the changing conditions of the pandemic, causing major disruptions in trial conduct. Some trials have had to face the shutdown of trial sites, limited access to regulatory bodies, […]